Tango Launched with $55M to Exploit Sequencing and CRISPR Target Discovery – Genetic Engineering & Biotechnology News
Xconomy |
Tango Launched with $55M to Exploit Sequencing and CRISPR Target Discovery
Genetic Engineering & Biotechnology News Third Rock Ventures has launched a new cancer drug discovery and development company, Tango Therapeutics, with a $55 million Series A investment. The new firm is exploiting a platform that combines sequencing and CRISPR-based screening to identify … Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment New Cambridge biotech Tango aims to make cancer its own worst enemy |
